will step down and that the company is pulling back on selling its controversial Alzheimer’s drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.programme restricted coverage of the medicine to patients in clinical trials.
The company said it will retain minimal resources to make Aduhelm available to patients currently taking the drug in theMr Vounatsos, who was named as the CEO in 2016, will continue in his role until a successor is appointed, the company said. Under his leadership, the US biotech developed and launched several important growth drivers including spinal muscular atrophy drug Spinraza and multiple sclerosis drug Vumerity.
The company was betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to act as a buffer as its main established revenue drivers face rising competition.
Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Marketing company gets temporary injunctions allowing it back onto premisesRaw Marketing claims landlords unlawfully retook its offices in Ranelagh
Weiterlesen »